Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.78 |
| ▸ | RET | P07949 | 4/20 | 0.71 |
| ▸ | ABL2 | P42684 | 3/20 | 0.71 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.65 |
| ▸ | KDR | P35968 | 3/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.64 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.64 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.64 |
| ▸ | KIF5B | P33176 | 1/20 | 0.64 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.64 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.61 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31474781 | 1.00 | ABL1 (0.78) | ABL1RETABL2MAPK14FGFR1 | |
| SCHEMBL24283328 | 0.95 | ABL1 (0.79) | ABL1RETABL2MAPK14FGFR1 | |
| SCHEMBL31474786 | 0.95 | ABL1 (0.79) | ABL1RETABL2MAPK14FGFR1 | |
| SCHEMBL15061726 | 0.92 | ABL1 (0.67) | ABL1RETABL2MAPK14FGFR1 | |
| SCHEMBL10207568 | 0.92 | ABL1 (0.79) | ABL1RETABL2MAPK14FGFR1 | |
| SCHEMBL21843575 | 0.91 | ABL1 (0.76) | ABL1RETABL2MAPK14FGFR1 | |
| SCHEMBL31474783 | 0.91 | ABL1 (0.76) | ABL1RETABL2MAPK14FGFR1 | |
| SCHEMBL21843651 | 0.91 | RET (0.72) | ABL1RETABL2MAPK14FGFR1 | |
| SCHEMBL21843525 | 0.89 | RET (0.70) | ABL1RETABL2MAPK14FGFR1 | |
| SCHEMBL15061738 | 0.89 | ABL1 (0.77) | ABL1RETABL2MAPK14NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089599-A1 | ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2022-03-24 | — | — | US | disclosed |
| CN-113227094-A | Alkynyl nicotinamide compounds as kinase inhibitors | 普渡研究基金会 | 2021-08-06 | — | — | CN | disclosed |
| WO-2020053812-A1 | ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089599-A1 | ALKYNYL NICOTINAMIDE COMPOUNDS AS KINASE INHIBITORS | NADK, NAMPT, NME2 | ABL1 22/4885RET 183/4885ABL2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.